 The purpose of this study is to evaluate whether adding an investigational medication called recombinant human parathyroid hormone rhPTH1-84 to standard hypoparathyroidism therapy oral calcium and active vitamin D tablets may result in superior improvements in symptoms of hypoparathyroidism assessed by hypoparathyroidism symptom diary HPT-SD symptom scale compared with standard therapy. 